ABLA
JAZZ icon

Alan B. Lancz & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Alan B. Lancz & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259K Hold
1,075
– – 0.23% 113
2026
Q1 		$203K Buy
+1,075
New +$188K 0.2% 128

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Alan B. Lancz & Associates's JAZZ Position: Q2 2026 in Review

Alan B. Lancz & Associates held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 1,075 shares worth $259K. The position accounts for 0.23% of the portfolio, ranked #113.

Alan B. Lancz & Associates first reported a position in JAZZ in Q1 2026 and has held it in 2 quarters since. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Alan B. Lancz & Associates held 1,075 shares of Jazz Pharmaceuticals worth $259K as of Q2 2026.
  • Alan B. Lancz & Associates left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up 0.23% of Alan B. Lancz & Associates's portfolio in Q2 2026, its #113 holding.
  • Alan B. Lancz & Associates first reported a position in Jazz Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Alan B. Lancz & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.